Abstract 17099: Impact of Non-alchoholic Fatty Liver Disease on Cardiovascular Events in Patients With Ischemic Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) has been reported to be associated with cardio-metabolic risk independent of established risk factors or the metabolic syndrome. However, it is unclear whether that NAFLD is capable of becoming cardiac risk factors for recurrent events in patients with ischemic heart disease. The aim of this study was to evaluate the role of NAFLD in predicting major adverse cardiovascular events (MACEs) in patients undergoing percutaneous coronary intervention (PCI).
Methods: A total of 140 consecutive patients undergoing PCI and abdominal ultrasonography were enrolled. All patients received optical medical therapy with the guideline. In addition to conventional gray scale analysis, integrated backscatter (IB) IVUS analyses were performed to determine plaque component (lipid, fibrous, and calcification). MACEs were defined as cardiac death, non-fatal myocardial infarction, and revascularization for the new lesion events.
Results: NAFLD was detected in 12.9% (n=18) of the total study population. Baseline characteristics were no significant differences between the 2 groups except for higher triglycerides and ALT level in NAFLD group. Percent lipid volume detected by IB IVUS in patients with NAFLD was greater compared with Non-NAFLD, while total plaque volume detected by gray scale IVUS had no differentiation between 2 groups. During follow-up period (median 847 days), the overall incidence of MACE was observed in 10% (n=14) of enrolled patients. MACEs were 27.8% in the NAFLD group and 9.0% in the non NAFLD group (p<0.01 by log-rank test). Revascularization for the new lesion events was 27.8% in NAFLD and 5.7% in Non-NAFLD (p<0.01). In the Cox model after adjustment of confounding factors (age and gender), prevalence of NAFLD (HR: 5.36, 95% CI: 1.07-27.0, p=0.04) was significantly and independently associated with incidence of MACEs.
Conclusions: NAFLD independently predicts MACEs in patients undergoing PCI with DES.
- © 2013 by American Heart Association, Inc.